ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
The Eye on the Future Forum (EFF) is a platform hosted by ProQR on innovative clinical development approaches for genetic eye diseases. This Fall Summit will explore the Science of RNA Therapies.
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
The 2021 annual general meeting (AGM) of shareholders of ProQR Therapeutics
will take place on Wednesday, May 19, 2021, at 16:00 hours CET/10:00am EDT.